Novo Nordisk A/S ADR
(NVO)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,142,868 | 7,598,139 | 5,846,789 | 4,011,327 | 2,046,188 |
| Depreciation Amortization | 248,820 | 958,578 | 625,360 | 420,487 | 223,212 |
| Accounts receivable | N/A | -2,053,822 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | 501,642 | N/A | N/A | N/A |
| Other Working Capital | 285,464 | -1,377,170 | 322,275 | 281,892 | -182,525 |
| Other Operating Activity | 879,617 | 3,123,133 | 2,407,072 | 1,204,565 | -262,439 |
| Operating Cash Flow | $3,556,769 | $8,750,500 | $9,201,496 | $5,918,271 | $1,824,436 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -278,226 | 186,465 | 150,353 | 124,493 | 59,491 |
| PPE Investments | -229,216 | -1,007,898 | -679,760 | -504,293 | -227,264 |
| Net Acquisitions | N/A | -2,908,825 | N/A | N/A | N/A |
| Purchase Of Investment | -1,056 | -1,131,678 | -1,091,961 | -609,334 | -381,583 |
| Sale Of Investment | 260,130 | N/A | 317 | 486 | 162 |
| Purchase Sale Intangibles | -39,208 | -167,055 | -124,501 | -44,091 | -15,724 |
| Other Investing Activity | -39,208 | -166,419 | -123,866 | -43,443 | -15,075 |
| Investing Cash Flow | $-287,576 | $-5,028,355 | $-1,744,917 | $-1,032,091 | $-564,270 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 1,676,896 | N/A | 1,531,600 | N/A | N/A |
| Debt Issued | 4,524 | 3,525,656 | 13,005 | 1,565,400 | -56,573 |
| Debt Repayment | -1,938,534 | -1,064,220 | -1,003,779 | -984,271 | N/A |
| Common Stock Repurchased | -675,132 | -3,094,018 | -1,892,891 | -1,361,640 | -479,816 |
| Dividend Paid | -2,366,052 | -3,423,355 | -3,412,596 | -2,187,702 | -2,187,540 |
| Other Financing Activity | 412,740 | 1 | 0 | 0 | 377,532 |
| Financing Cash Flow | $-2,885,558 | $-4,055,936 | $-4,764,661 | $-2,968,213 | $-2,346,397 |
| Exchange Rate Effect | -8,294 | 94,028 | 46,153 | 27,395 | 24,963 |
| Beginning Cash Position | 1,616,425 | 1,945,157 | 1,939,044 | 1,981,835 | 1,981,835 |
| End Cash Position | 1,991,766 | 1,705,393 | 4,677,114 | 3,927,197 | 920,566 |
| Net Cash Flow | $375,341 | $-239,764 | $2,738,070 | $1,945,362 | $-1,061,269 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,556,769 | 8,750,500 | 9,201,496 | 5,918,271 | 1,824,436 |
| Capital Expenditure | -229,216 | -1,007,898 | -679,760 | -504,293 | -227,264 |
| Free Cash Flow | 3,327,553 | 7,742,602 | 8,521,736 | 5,413,978 | 1,597,172 |